CN1273123C - (3r,4r)－△8－四氢大麻酚－11－酸在制备用于减少细胞增殖的药物的用途 - Google Patents

(3r,4r)－△8－四氢大麻酚－11－酸在制备用于减少细胞增殖的药物的用途 Download PDF

Info

Publication number
CN1273123C
CN1273123C CNB018130100A CN01813010A CN1273123C CN 1273123 C CN1273123 C CN 1273123C CN B018130100 A CNB018130100 A CN B018130100A CN 01813010 A CN01813010 A CN 01813010A CN 1273123 C CN1273123 C CN 1273123C
Authority
CN
China
Prior art keywords
cell
acid
thc
cell proliferation
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018130100A
Other languages
English (en)
Chinese (zh)
Other versions
CN1447685A (zh
Inventor
萨姆纳·伯斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lawrence Rachel
Robert B Julier
TG Therapeutics Inc
Original Assignee
Lawrence Rachel
Robert B Julier
Atlantic Technology Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence Rachel, Robert B Julier, Atlantic Technology Ventures Inc filed Critical Lawrence Rachel
Publication of CN1447685A publication Critical patent/CN1447685A/zh
Application granted granted Critical
Publication of CN1273123C publication Critical patent/CN1273123C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
CNB018130100A 2000-05-17 2001-05-17 (3r,4r)－△8－四氢大麻酚－11－酸在制备用于减少细胞增殖的药物的用途 Expired - Fee Related CN1273123C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
US60/204,935 2000-05-17

Publications (2)

Publication Number Publication Date
CN1447685A CN1447685A (zh) 2003-10-08
CN1273123C true CN1273123C (zh) 2006-09-06

Family

ID=22760084

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018130100A Expired - Fee Related CN1273123C (zh) 2000-05-17 2001-05-17 (3r,4r)－△8－四氢大麻酚－11－酸在制备用于减少细胞增殖的药物的用途
CNB018129161A Expired - Fee Related CN1227007C (zh) 2000-05-17 2001-05-17 大麻素药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018129161A Expired - Fee Related CN1227007C (zh) 2000-05-17 2001-05-17 大麻素药物

Country Status (13)

Country Link
US (2) US6448288B1 (enExample)
EP (2) EP1307186A4 (enExample)
JP (2) JP2003533479A (enExample)
CN (2) CN1273123C (enExample)
AT (1) ATE406156T1 (enExample)
AU (5) AU6468001A (enExample)
CA (2) CA2409005A1 (enExample)
DE (1) DE60135557D1 (enExample)
HU (2) HUP0700038A2 (enExample)
IL (3) IL152892A0 (enExample)
NZ (2) NZ523029A (enExample)
RU (2) RU2272620C2 (enExample)
WO (3) WO2001087297A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
EP1509250B1 (en) * 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
WO2006065792A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
ES2398676T3 (es) 2007-12-07 2013-03-20 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Also Published As

Publication number Publication date
IL152891A0 (en) 2003-06-24
WO2001087295A8 (en) 2003-04-10
RU2272620C2 (ru) 2006-03-27
EP1307188B1 (en) 2008-08-27
CN1452485A (zh) 2003-10-29
WO2001087295A1 (en) 2001-11-22
IL152892A (en) 2010-06-30
CN1447685A (zh) 2003-10-08
EP1307186A1 (en) 2003-05-07
AU2001261695B2 (en) 2005-06-16
RU2273476C2 (ru) 2006-04-10
NZ523028A (en) 2004-09-24
NZ523029A (en) 2004-11-26
US20040225011A1 (en) 2004-11-11
AU2001263217A1 (en) 2001-11-26
HUP0700038A2 (en) 2007-05-02
US20020022653A1 (en) 2002-02-21
JP2003533478A (ja) 2003-11-11
IL152892A0 (en) 2003-06-24
DE60135557D1 (de) 2008-10-09
AU6169501A (en) 2001-11-26
EP1307188A4 (en) 2005-07-06
JP2003533479A (ja) 2003-11-11
AU2001264680B2 (en) 2006-09-14
HUP0700039A2 (en) 2007-05-02
WO2001087296A1 (en) 2001-11-22
WO2001087297A1 (en) 2001-11-22
CA2409005A1 (en) 2001-11-22
ATE406156T1 (de) 2008-09-15
US6914072B2 (en) 2005-07-05
US6448288B1 (en) 2002-09-10
EP1307186A4 (en) 2005-10-19
EP1307188A1 (en) 2003-05-07
AU6468001A (en) 2001-11-26
CA2408961A1 (en) 2001-11-22
CN1227007C (zh) 2005-11-16

Similar Documents

Publication Publication Date Title
US6448288B1 (en) Cannabinoid drugs
Chayasirisobhon Mechanisms of action and pharmacokinetics of cannabis
AU2001261695A1 (en) Methods for decreasing cell proliferation based on (3R, 4R)-delta8-tetrahydrocannabinol-11-oic acids
AU2001264680A1 (en) Cannabinoid drugs
Fan et al. PERK, beyond an unfolded protein response sensor in estrogen-induced apoptosis in endocrine-resistant breast cancer
Recht et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid
JPS6038324A (ja) 脂肪酸組成物
JP2001507363A (ja) イソプレノイド類とスタチン類との組合せによる腫瘍成長抑制方法
Mudit et al. Cancer control potential of marine natural product scaffolds through inhibition of tumor cell migration and invasion
Zeddou Osteoarthritis Is a Low‐Grade Inflammatory Disease: Obesity’s Involvement and Herbal Treatment
WO2005034937A1 (en) Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent
US6974835B2 (en) Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
Limbach et al. Baicalein activates 5’adenosine monophosphate-activated protein kinase, inhibits the mammalian target of rapamycin, and exhibits antiproliferative effects in pancreatic neuroendocrine tumors in vitro and in vivo
Nixon Cancer, cancer cachexia, and diet: lessons from clinical research
Shapiro et al. Effect of aromatic retinoids on rat chondrosarcoma glycosaminoglycan biosynthesis
US20060182828A1 (en) Methods of reducing lipid peroxidation and achieving related health benefits by the administration of tocopherol and sesame lignans
CN113368105A (zh) 鸦胆子苦醇在制备用于抑制口腔鳞癌细胞的糖酵解代谢和线粒体呼吸的药物中的应用
Tirapelli et al. Mechanisms underlying the biphasic effect of vitamin K1 (phylloquinone) on arterial blood pressure
CA2407442A1 (fr) Nouveaux medicaments a base de melanges de sesquiterpenes
Gleissman Lipid mediators in the prevention and therapy of neuroblastoma
TW202005647A (zh) 環氧化酶－２抑制劑及含此之醫藥組成物暨其應用
JPH03133926A (ja) 癌転移抑制剤
TW200800165A (en) Breast cancer cell inhibiting agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee